HAIFA, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has been informed by the Tel Aviv Stock Exchange (TASE) that its shares are now listed in both the Tel-Aviv-75 (TA-75) and the Tel Aviv-100 (TA-100) Index effective December 16, 2012. The TA-100 index tracks the top 100 companies listed on TASE weighted by market capitalization. "We are proud to be included in this important Tel Aviv Stock Exchange index and to become one of the 100 most highly capitalized companies on the exchange," said Zami Aberman, Chairman and CEO of Pluristem. "Our inclusion in this index positions us as one of the top Israeli-based biotechnology companies and is another step in our evolution as a leading global publicly traded biotech company. Additionally, this designation places us on the radar screen of many Israeli fund managers, in particular those who follow and track this index." About TA-75 The TA-75 Index is one of the TASE's leading indices, published from 1999. The index tracks the 75 shares with the highest market capitalization not included in the TA-25 index. About TA-100 The TA-100 Index is one of the TASE's leading indices, published from 1992. The index consists of the 100 shares with the highest market capitalization that are included in the TA-25 and TA-75 indices. About Pluristem Therapeutics Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.